A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR)
Open Access
- 12 June 2020
- journal article
- research article
- Published by Springer Nature in Radiation Oncology
- Vol. 15 (1) , 1-8
Abstract
Background: Chemoradiotherapy remains the standard of care for locally advanced rectal cancer. Efforts to intensify treatment and increase response rates have yet to yield practice changing results due to increased toxicity and/or absence of increased radiosensitization. Enadenotucirev (EnAd) is a tumour selective, oncolytic adenovirus which can be given intravenously. Pre-clinical evidence of synergy with radiation warrants further clinical testing and assessment of safety with radiation. Methods: Eligibility include histology confirmed locally advanced rectal cancer that require chemoradiation. The trial will use a Time-to-Event Continual Reassessment Model-based (TiTE-CRM) approach using toxicity and efficacy as co-primary endpoints to recommend the optimal dose and treatment schedule 30 patients will be recruited. Secondary endpoints include pathological complete response the neoadjuvant rectal score. A translational program will be based on a mandatory biopsy during the second week of treatment for ‘proof-of-concept’ and exploration of mechanism. The trial opened to recruitment in July 2019, at an expected rate of 1 per month for up to 4 years. Discussion: Chemoradiation with Enadenotucirev as a radiosensitiser in locally Advanced Rectal cancer (CEDAR) is a prospective multicentre study testing a new paradigm in radiosensitization in rectal cancer. The unique ability of EnAd to selectively infect tumour cells following intravenous delivery is an exciting opportunity with a clear translational goal. The novel statistical design will make efficient use of both toxicity and efficacy data to inform subsequent studies. Trial registration: ClinicalTrial.gov, NCT03916510. Registered 16th April 2019.Keywords
Funding Information
- Cancer Research UK (C43735/A24474)
This publication has 42 references indexed in Scilit:
- EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II studyGastrointestinal Endoscopy, 2012
- Phase IB Study of Gene-Mediated Cytotoxic Immunotherapy Adjuvant to Up-Front Surgery and Intensive Timing Radiation for Malignant GliomaJournal of Clinical Oncology, 2011
- Serotype-Specific Inactivation of the Cellular DNA Damage Response during Adenovirus InfectionJournal of Virology, 2011
- Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancerInternational Journal of Radiation Biology, 2010
- Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon CancerPLOS ONE, 2008
- Ionizing radiation enhances adenoviral vector expressing mda‐7/IL‐24‐mediated apoptosis in human ovarian cancerJournal of Cellular Physiology, 2006
- Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificityCancer Gene Therapy, 2005
- A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the ExtremitiesClinical Cancer Research, 2004
- TNFerade Biologic, an Adenovector With a Radiation-Inducible Promoter, Carrying the Human Tumor Necrosis Factor Alpha Gene: A Phase I Study in Patients With Solid TumorsJournal of Clinical Oncology, 2004
- Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) proteinCancer Gene Therapy, 2003